Answers are grounded in this paper and cite their sources.
Investigation reveals alteplase-loaded platelets exert fibrinolytic effects, indicating their potential in drug delivery systems for thromboembolism.
The utilization of alteplase for the management of intracerebral thromboembolism is associated with an elevated risk of intracerebral hemorrhage. To mitigate this risk, we investigated the fibrinolytic effect of alteplase-loaded platelets as a preliminary step in the development of a biocompatible drug delivery system (DDS). In this context, the objective of this study was to ascertain whether alteplase could be loaded to platelets, identify any functional alterations in alteplase-loaded platelets, and determine whether alteplase-loaded platelets exert fibrinolytic effects. Fluorescent alteplase was incubated with platelets, and the resulting fluorescence was observed and quantified. The expression of CD62P on platelets in response to adenosine diphosphate (ADP) stimulation was quantified as an indicator of platelet activation. Moreover, alterations in whole blood viscosity and plasma absorbance were monitored throughout the coagulation process with alteplase-treated platelets. Consequently, the fluorescent-labeled alteplase was observed with the platelets, indicating that it had been successfully loaded to the platelets. Furthermore, following stimulation with ADP, platelets that had loaded with alteplase expressed CD62P. The intracellular concentration of alteplase was observed to decline in response to ADP stimulation. The fibrinolytic activity of alteplase-loaded platelets was demonstrated in whole blood and plasma. Therefore, a drug DDS that employs alteplase-loaded platelets may offer a promising avenue for the development of a more biocompatible and less invasive thrombolytic therapy.
No takes yet. Share an insight, caveat, or question.
Inoue et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: